Navigation Links
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
Date:12/16/2008

s also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms -- aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the National Cancer Institute's SEER database there were nearly 400,000 people in the U.S. with NHL in 2004. The American Cancer Society estimates that in the United Stat
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R)
2. Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client
3. Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG
4. Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes
5. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
6. Transition Therapeutics Announces Dates for Upcoming Corporate Events
7. Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer
8. Precision Therapeutics Secures $43 Million in Venture Capital Funding
9. Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results
10. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
11. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... This prestigious award is given ... made outstanding and innovative contributions to the physical ... private practice physical therapy by the Private Practice ... On behalf of Performance Physical Therapy, Michelle Collie ... Performance accepted the award at the Private Practice, ...
(Date:12/17/2014)... 17, 2014 In its comprehensive analysis ... its Argus Claim Review division have recently identified out-of-network ... common ways savings are achieved on behalf of employer-clients. ... of dollars in savings to Argus each year, with ... As explained by Tom Doney, Cypress president and CEO, ...
(Date:12/17/2014)... Project Veritas is releasing a video interview ... economist and Obamacare architect Jonathan Gruber to public attention. ... interview, which is being distributed on YouTube. , During ... in the Affordable Care Act in order to hide ... dollar per year tax grab. , “President Obama promised ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Expectant parents should leave prenatal ... Administration recommends. Use of ultrasound imaging and heartbeat ... entirely risk-free, the agency warns. "Although there ... to ultrasound imaging and heartbeat monitors, prudent use of ... Shahram Vaezy, an FDA biomedical engineer, said in an ...
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, 2014 ... a new study reveals that states that routinely perform randomized ... on their roads. The finding suggests that states that ... deter inebriated revelers from getting behind the wheel in the ... regarding drinking and driving," said study lead author James Fell, ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3
... proven effective, tamoxifen could be new way to fight ... drug used to help prevent recurring breast cancer appears to ... research has found. , University of Rochester Medical Center researchers ... infections, which can be fatal to people with compromised ...
... NEW YORK, July 24 Empire BlueCross BlueShield and Stony ... reached agreement for a new contract, effective August 1, 2009. ... access to Stony Brook Hospital as in-network. , ... the long-standing relationship we have with Stony Brook," noted Mark ...
... WASHINGTON, July 24 Speaker Nancy Pelosi issued ... to fund the Departments of Labor, Health and Human Services, Education, ... federal funding for needle exchange, passed in the House by a ... "The fiscal year 2010 Labor-Health and Human Services-Education appropriations ...
... , , WEST ... Hollywood will never go away. Despite the poor economy, a ... the American Society of Plastic Surgeons. One would think the ... to take better care of their skin, but unfortunately summertime in ...
... , , , PORTLAND, ... has selected Artefill, the first and only FDA-approved microsphere-enhanced collagen filler for ... user the past several years due to its proven success and effectiveness ... , Dr. Vu commented, "Artefill is a great product for ...
... , , , LANCASTER, ... 32 filed cases around the country have filed a joint motion asking ... Judge James G. Carr of the United States District Court for the ... 2009, before the Judicial Panel on Multidistrict Litigation in Washington, D.C. , ...
Cached Medicine News:Health News:Breast Cancer Drug May Beat Fungal Infection 2Health News:Pelosi Statement on House Passage of Labor, HHS, Appropriations Bill, Which Lifts Ban on Needle Exchange 2Health News:It Isn't Just Vanity! Local MedSpa Seeks to Correct and Educate. 2Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Motion Filed to Consolidate Yasmin/YAZ Litigation in Toledo, Ohio 2
(Date:12/17/2014)... BUENA, N.J. , Dec. 17, 2014  IGI ... announced today the closing of its offering of $125 ... due 2019 (the "Notes").  The Notes were offered and ... 144A under the Securities Act of 1933, as amended ... at a fixed rate of 3.75% per year, payable ...
(Date:12/17/2014)... Dec. 17, 2014 PCCA received the ... ( http://bit.ly/1382OkS ) program seal for best practices ... program highlights medical practices, materials and goods that ... Children affected by autism often have ... exacerbated by ingredients found in food and medicine ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... of the "Electrocardiogram (ECG) Devices - Global Trends, ... http://photos.prnewswire.com/prnh/20130307/600769 ... US$330 million by 2016. The North America ... global market share while Europe ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... April 27, 2012  Hill-Rom Holdings, Inc. (NYSE: HRC ... the Deutsche Bank Securities Health Care Conference in Boston on ... are invited to listen to the live discussion via the ... at http://www.media-server.com/m/p/2sfzaj9g . A recorded replay of the discussion ...
... Presented today by Tribeca Film Festival co-founder Craig ... Professor Clay Christensen and the Disruptor Foundation, Hanger ... CP, FAAOP and Area Practice Manager Dan Strzempka, ... Award.  Carroll and Strzempka received the award for ...
Cached Medicine Technology:Hanger clinicians honored with 2012 Tribeca Disruptive Innovation Award 2